Margetuximab clinical trials
Also written MGAH22 and Margenza.
How each study uses margetuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Dec 2020 · MARGENZA · BLA 761150 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
MacroGenics (6) · Dana-Farber Cancer Institute (1) · Zai Lab (Shanghai) Co., Ltd. (1) · MedSIR (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses margetuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04425018Written as MargetuximabHow we know
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedPhase 2/3MacroGenicsNCT04082364Written as margetuximabHow we know
- Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerCompletedPhase 1/2MacroGenicsNCT02689284Written as Margetuximab 10 mg/kgHow we know
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerCompletedPhase 3MacroGenicsNCT02492711Written as MargetuximabHow we know
- Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerCompletedPhase 2MacroGenicsNCT01828021Written as MargetuximabHow we know
- Safety Study of MGAH22 in HER2-positive CarcinomasCompletedPhase 1MacroGenicsNCT01148849Written as margetuximabHow we know
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedPhase 1MacroGenicsNCT03219268Written as margetuximabHow we know
- A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCActive, not recruitingPhase 2Zai Lab (Shanghai) Co., Ltd.NCT04262804Written as MargetuximabHow we know
- Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnPhase 2MedSIRNCT05227131Written as MargetuximabHow we know
Codes
What other systems call margetuximab · ClinicalTrials.gg INT000659
- MeSH (NLM) C000617981margetuximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K911R84KEWMARGETUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2473851One source FDA
- Wikidata Q109356831MargetuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91733MargetuximabOne source FDA
- DrugBank DB14967One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000617981 | margetuximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K911R84KEW | MARGETUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2473851 | — | One source FDA |
| Wikidata | Q109356831 | Margetuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91733 | Margetuximab | One source FDA |
| DrugBank | DB14967 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.